Job title: Director, Functional Screening
Helene joined UCB (then Celltech) in 1989 and has since gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets. Helene now leads the UCB Bispecific Target Discovery team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.